2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, APL, MDS, MPN, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6336 Patterns of allogeneic hematopoietic cell transplantation referral and utilization in acute myeloid leukemia: Clinical, social, and survival outcomes in a contemporary cohort

Haley Brooke Thigpen, MD, Kendall Diebold, CNP, MSN2, Jessica Pia, MD3, Gnyata Patel, MD4, Leighann Boothe, MD5, Kirsten Maddox6, Aditi Sharma, MD7, Razan Mohty, MD8, Manuel Ricardo Espinoza-Gutarra, MD9, Zaid Al-Kadhimi, MD10, Antonio Di Stasi11, Donna Salzman, MD12, Pankit Vachhani, MD13, Sravanti Rangaraju, MD14, Kimo Bachiashvili, MD15, Ravi Bhatia, MD16, Jorge Cortes, MD17, Omer Jamy, MD18
1 The University of Alabama at Birmingham, Birmingham, Alabama, United States
2 The University of Alabama at Birmingham, Birmingham, Alabama, United States
3 The University of Alabama at Birmingham, Birmingham, Alabama, United States
4 The University of Alabama at Birmingham, Birmingham, Alabama, United States
5 The University of Alabama at Birmingham, Birmingham, Alabama, United States
6 The University of Alabama at Birmingham, Birmingham, Alabama, United States
7 The University of Alabama at Birmingham, Birmingham, Alabama, United States
8 The University of Alabama at Birmingham, Birmingham, Alabama, United States
9 The University of Alabama at Birmingham, Birmingham, Alabama, United States
10 The University of Alabama at Birmingham, Birmingham, Alabama, United States
11 The University of Alabama at Birmingham, Birmingham, Alabama, United States
12 The University of Alabama at Birmingham, Birmingham, Alabama, United States
13 The University of Alabama at Birmingham, Birmingham, Alabama, United States
14 The University of Alabama at Birmingham, Birmingham, Alabama, United States
15 The University of Alabama at Birmingham, Birmingham, Alabama, United States
16 The University of Alabama at Birmingham, Birmingham, Alabama, United States
17 The University of Alabama at Birmingham, Birmingham, Alabama, United States
18 The University of Alabama at Birmingham, Birmingham, Alabama, United States

Background

Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative therapy for many patients with acute myeloid leukemia (AML). However, barriers between transplant eligibility, referral, and actual transplantation remain poorly characterized. We evaluated referral patterns, receipt of transplantation, and survival in a contemporary AML cohort.

Methods

We performed a retrospective analysis of 1,113 patients with AML diagnosed between January 2017 - March 2026 at a large academic medical center. Referral status, transplant utilization, documented barriers to transplantation, and survival outcomes were assessed. Overall survival was evaluated using Cox proportional hazards incorporating transplantation as a time-dependent covariate.

Results

Among 1,113 patients (median follow-up of 16 months), 558 (50.1%) were referred for allo-HCT, 527 (47.3%) were not referred and referral status was unavailable for 28 (2.5%). Median time from diagnosis to referral was 29 days. Median age was 65 years (referred=59 years, not referred=71 years) with 83% ≤75 years. The cohort was predominantly White (71.7%), followed by Black (22.2%). ELN 2022 risk stratification was favorable in 23.5%, intermediate in 25.9%, adverse in 49.3% and unavailable in 1.3% patients.

Among non-referred patients, the most common reasons were advanced age (30.6%), early relapse/death (25.6%) and comorbidities (17.1%). Referrals declined with age (73.1% <60 years, 62.3% age 60–69, 41.1% age 70–74, and 4.2% ≥75 years; p<0.001) but did not differ by sex or race. Referral rates decreased across increasing Social Vulnerability Index (SVI) quartiles, from 62% in Q1 (least vulnerable) to 47% in Q4 (most vulnerable) (p=0.02).

Among 558 referred patients, 261 (46.8%) underwent allo-HCT, representing 23% of the overall cohort. Among referred intermediate- and adverse-risk patients, 59.5% and 45.5% proceeded to transplant, respectively. Median time from diagnosis to transplantation was 182 days (IQR, 133-345) and from referral to transplantation was 127 days (IQR, 93-189). The most common reasons for not proceeding to transplant following referral were relapse or death (39.8%), comorbidities (17.6%), socioeconomic or insurance barriers (11.8%), patient refusal (10.1%) and physician decision (8.5%). Among referred patients, transplant receipt demonstrated a significant decline across increasing SVI quartiles (Q1–Q4: 65%, 52%, 46%, and 44%, respectively; p=0.027). Among referred patients, those who underwent transplant were younger than those who did not proceed to transplant (median age 56 vs. 62 years, p<0.001). Transplanted patients were more likely to have ELN intermediate-risk disease (27.2% vs. 18.1%, p=0.013). The prevalence of ELN adverse-risk disease was similar between groups (59.4% vs. 60.2%, p=0.913).

Overall, increasing age independently reduced the likelihood of transplantation (OR 0.94, 95% CI 0.93–0.95; p<0.001). Compared with adverse-risk AML, favorable-risk AML was associated with significantly lower odds of transplantation (OR 0.28, 95% CI 0.17–0.45; p<0.001), whereas intermediate-risk AML was not. In multivariable Cox analysis, transplantation was independently associated with improved overall survival (HR 0.43, 95% CI 0.32–0.58; p<0.001). Compared with adverse-risk AML, intermediate-risk (HR 0.57, p<0.001) and favorable-risk AML (HR 0.35, p<0.001) had superior survival, whereas age was not independently associated with survival (HR 1.005, p=0.19).

Conclusions

In this large single-center AML cohort, half of patients were referred for transplant evaluation, and fewer than half of referred patients ultimately underwent allo-HCT. Advanced age, early relapse/death and comorbidity burden were the principal contributors to non-referral, whereas relapse or death, comorbidities and socioeconomic or insurance barriers were the predominant barriers among referred patients. Increasing social vulnerability was associated with reduced referral and a stepwise decline in transplant receipt among referred patients, highlighting potential disparities in access to curative therapy. Despite substantial attrition between referral and transplant receipt, allo-HCT remained independently associated with improved survival, highlighting the need for strategies to reduce disease-related and system-level barriers that prevent eligible patients from reaching transplantation.

Haley Brooke Thigpen, MD: No relevant conflicts of interest to declare.